TNFSF10 and neoplasm: We tested this by combining CY-treatment in nude mice with agonistic anti-DR5 antibodies (clone MD5-1) [35], [36], reasoning that CY-sensitized tumor cells would then be killed by antibody-mediated DR5 ligation, compensating for the lack of T cell derived TRAIL.